Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Year in review

- PMLiVE

NHS urges people yet to receive their COVID-19 booster to come forward

Sunday 12 February is the last day people under 50 years of age who are not considered at risk can receive a booster

- PMLiVE

Fishawack Health welcomes Mario Muredda as its new President of Marketing

Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.

Avalere Health

- PMLiVE

JCVI recommends autumn COVID-19 vaccine booster for those at highest risk

After high uptake for the initial booster dose in December 2021, further uptake has been low

Diversifying Healthcare AI with Federated Learning

Dr. Ittai Dayan, Co-founder & CEO of Rhino Health, shares how his company is transforming the way healthcare AI solutions are created, adopted and measured. He will also explore how...

Impetus Digital

- PMLiVE

World Health Organization releases latest set of COVID-19 guidelines

The guidelines include advice on treatments, isolation periods and wearing masks

- PMLiVE

FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine

Preliminary data showed a possible link between the updated vaccine and a higher risk of stroke

A doctor and a patient discussing something whilst looking at the ipad the doctor is holding.

The impact of mindset on digital product success: Download our new whitepaper

Six months on from releasing our research report, we reflect on the themes raised and offer practical advice on how contradictions can be overcome to enable digital success in pharma...

Graphite Digital

Virtual Tools for Promoting Diversity in Pharma and Clinical Trials

It is no secret that Pharma (still) has a major diversity problem.

Impetus Digital

- PMLiVE

GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates

The vaccines produced promising preliminary results in phase 1 trials

- PMLiVE

WHO reports new Omicron subvariant cases detected in 29 countries worldwide

The new Omicron subvariant is spreading rapidly in the US

- PMLiVE

Valneva reports additional data for COVID-19 booster

VLA2001 was well tolerated in participants previously vaccinated with an mRNA vaccine

- PMLiVE

Novavax initiates phase 2 combination COVID-19/flu vaccine study

Initial results from the trial are expected towards the middle of the year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links